Antibiotic

/Tag:Antibiotic

CELLULITIS: MEDICAL RESPONSIBILITY IN SELECTING ANTIBIOTICS

Background: Despite detailed Infectious Disease Society of America (IDSA) skin and soft tissue infection guidelines, patients with cellulitis at our institution consistently receive antibiotics with high local resistance or that are inappropriate based on IDSA [...]

By | 2017-04-20T17:37:04+00:00 April 20th, 2017|Innovations Abstracts, Quality Improvement|Comments Off on CELLULITIS: MEDICAL RESPONSIBILITY IN SELECTING ANTIBIOTICS

ECONOMIC BURDEN OF OVERT HEPATIC ENCEPHALOPATHY AND PHARMACOECONOMIC IMPACT OF RIFAXIMIN

Background: Hepatic encephalopathy (HE) is a common neurological complication in patients with cirrhosis. In addition to numerous morbidity-related issues, HE is associated with substantial economic burden. Treatment includes lactulose or rifaximin, a nonsystemic antibiotic that [...]

By | 2018-03-19T12:52:34+00:00 March 19th, 2018|Hospital Medicine 2018, Research, Value in Hospital Medicine|Comments Off on ECONOMIC BURDEN OF OVERT HEPATIC ENCEPHALOPATHY AND PHARMACOECONOMIC IMPACT OF RIFAXIMIN

HOW MANY OUTPATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA BECOME INPATIENTS? A U.S. HEALTH INSURANCE CLAIM ANALYSIS FROM 2011-2015

Background: Approximately 1-2% of the U.S. population gets community-acquired pneumonia (CAP) annually in the U.S. and CAP is associated with substantial mortality, morbidity and costs.  While the incidence of CAP is well-defined, the incidence of [...]

By | 2017-04-26T01:14:27+00:00 April 20th, 2017|Research Abstracts, Translating Research into Practice|Comments Off on HOW MANY OUTPATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA BECOME INPATIENTS? A U.S. HEALTH INSURANCE CLAIM ANALYSIS FROM 2011-2015

PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE WITH RIFAXIMIN ALONE VERSUS RIFAXIMIN PLUS LACTULOSE THERAPY: IMPACT ON QUALITY OF LIFE AND CAREGIVER BURDEN IN PATIENTS WITH CIRRHOSIS

Background: Rifaximin, a nonsystemic antibiotic, may be used alone or in combination with lactulose for reducing the risk of overt hepatic encephalopathy (OHE) recurrence in adults. This analysis evaluated rifaximin alone and rifaximin + lactulose [...]

By | 2018-03-19T15:44:00+00:00 March 19th, 2018|Research, Transitions of Care, Uncategorized|Comments Off on PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE WITH RIFAXIMIN ALONE VERSUS RIFAXIMIN PLUS LACTULOSE THERAPY: IMPACT ON QUALITY OF LIFE AND CAREGIVER BURDEN IN PATIENTS WITH CIRRHOSIS

RIFAXIMIN ALONE VERSUS RIFAXIMIN AND LACTULOSE COMBINATION THERAPY FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: SAFETY PROFILE IN PATIENTS WITH CIRRHOSIS

Background: Rifaximin 550 mg tablets is a nonsystemic antibiotic indicated for reducing the risk of overt hepatic encephalopathy (OHE) recurrence in adults and may be used alone or in combination with the cathartic lactulose. This [...]

By | 2019-03-11T14:21:17+00:00 March 11th, 2019|Hospital Medicine 2019, Patient Safety, Research|Comments Off on RIFAXIMIN ALONE VERSUS RIFAXIMIN AND LACTULOSE COMBINATION THERAPY FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: SAFETY PROFILE IN PATIENTS WITH CIRRHOSIS

THE TIP OF THE ICEBERG, ANTIBIOTIC STEWARDSHIP AND FLUOROQUINOLONE USE AT HOSPITAL DISCHARGE: A MULTI-HOSPITAL COHORT STUDY

Background: Inpatient antibiotic stewardship programs often use pre-prescription approval (PPA) or prospective audit and feedback (PAF) to reduce fluoroquinolone prescribing. Whether these stewardship strategies targeting inpatient fluoroquinolone use also influence prescribing at discharge is unknown. [...]

By | 2018-03-29T15:34:57+00:00 March 29th, 2018|Hospital Medicine 2018, Top 15 Research and Innovation Oral Abstracts|Comments Off on THE TIP OF THE ICEBERG, ANTIBIOTIC STEWARDSHIP AND FLUOROQUINOLONE USE AT HOSPITAL DISCHARGE: A MULTI-HOSPITAL COHORT STUDY